Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Top Page
Inovio Pharmaceuticals
(NASDAQ:INO)33Underperform
Positive Factors
Clinical Trial Results
The overall clinical response was 81%, with a significant number of patients experiencing a decrease in surgical interventions after INO-3107 administration.
Regulatory Approval
INO-3107 has been granted Breakthrough Therapy designation, which could qualify it for priority review.
Negative Factors
Financial Needs
The company may need to raise additional capital within the next 12 months.
Inovio Pharmaceuticals (INO) vs. S&P 500 (SPY)
Market Cap
$71.12M
Dividend YieldN/A
Average Volume (3M)714.44K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth-76.18%
EPS Growth40.70%
CountryUS
Employees122
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.48
Shares Outstanding36,099,990
10 Day Avg. Volume664,680
30 Day Avg. Volume714,442
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)252.77
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.50Price Target Upside435.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Inovio Pharmaceuticals Business Overview & Revenue Model
Company DescriptionInovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products to treat cancers and infectious diseases. Headquartered in Pennsylvania, Inovio leverages its proprietary platform to develop therapies that can stimulate an immune response against a wide array of pathogens and cancer cells. The company's core products include a pipeline of DNA medicines designed to provide robust and targeted immune system activation.
How the Company Makes MoneyInovio Pharmaceuticals makes money primarily through the development and commercialization of its DNA-based immunotherapies. The company generates revenue from licensing agreements, milestone payments, and collaborations with other pharmaceutical companies and research institutions. Inovio's partnerships often involve joint development projects where costs and potential royalties are shared, contributing to its earnings. Additionally, the company may receive funding from government grants and contracts for specific research projects, especially in the area of infectious disease vaccines. These collaborations and funding sources are crucial in supporting Inovio's research and development efforts and advancing its product candidates through clinical trials.
Inovio Pharmaceuticals Financial Statement Overview
Summary
Inovio Pharmaceuticals is experiencing significant financial difficulties characterized by declining revenues, high leverage, and negative cash flows. The company faces substantial operational and profitability challenges that may impact its financial health and ability to sustain operations without restructuring or external support.Income Statement
Inovio Pharmaceuticals exhibits declining revenue trends with negative margins. The TTM data indicates a significant gross profit loss and a net loss, reflecting challenges in managing operational costs and achieving profitability. Revenue growth has not been consistent, presenting a risk for sustainable financial performance.15
Very Negative
Balance Sheet
The company's balance sheet highlights high leverage with a substantial debt-to-equity ratio, indicating potential financial risk. The equity ratio has been decreasing over the years, pointing to reduced asset financing through equity. The negative net debt suggests reliance on cash reserves, but declining stockholders' equity raises concerns about long-term stability.20
Very Negative
Cash Flow
Inovio's cash flow statement reveals negative operating and free cash flow, underscoring difficulties in generating cash from operations. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting sales to cash. The company may face challenges in maintaining liquidity without external financing.18
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 203.41K | 832.01K | 10.26M | 1.77M | 7.41M | 4.11M | Gross Profit |
| -1.56M | -2.67M | 4.77M | -2.96M | -86.83M | -83.91M | EBIT |
| -119.42M | -143.94M | -267.57M | -301.22M | -124.08M | -111.11M | EBITDA |
| -109.89M | -130.39M | -270.90M | -296.56M | -149.56M | -107.34M | Net Income Common Stockholders |
| -25.25B | -135.12M | -287.66M | -305.38M | -215.09M | -120.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 145.29M | 145.29M | 253.00M | 401.31M | 411.64M | 89.53M | Total Assets |
| 170.95M | 170.95M | 348.53M | 495.94M | 539.77M | 143.95M | Total Debt |
| 30.21M | 30.21M | 32.07M | 33.02M | 39.05M | 99.51M | Net Debt |
| 15.90M | 15.90M | -14.25M | -38.12M | -211.68M | 77.31M | Total Liabilities |
| 53.60M | 53.60M | 126.17M | 96.27M | 78.63M | 138.55M | Stockholders Equity |
| 117.35M | 117.35M | 222.36M | 399.67M | 461.14M | 3.44M |
| Cash Flow | Free Cash Flow | ||||
| -84.44B | -124.69M | -217.18M | -216.94M | -179.50M | -98.84M | Operating Cash Flow |
| -84.44B | -124.37M | -216.22M | -215.71M | -177.98M | -97.85M | Investing Cash Flow |
| 69.45B | 87.36M | 109.59M | -175.34M | -58.80M | -9.04M | Financing Cash Flow |
| 24.17M | 5.00M | 81.84M | 211.50M | 465.28M | 105.40M |
Inovio Pharmaceuticals Technical Analysis
Negative
1.96
Price Trends
2.02
Negative
3.32
Negative
5.89
Negative
Market Momentum
-0.06
Positive
43.63
Neutral
31.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INO, the sentiment is Negative. The current price of 1.96 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.02, and below the 200-day MA of 5.89, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.63 is Neutral, neither overbought nor oversold. The STOCH value of 31.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INO.
Inovio Pharmaceuticals Risk Analysis
Inovio Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. Inovio Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inovio Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $27.51B | ― | -2.37% | ― | -52.11% | -118.03% | |
55 Neutral | $106.92M | ― | -103.37% | ― | 303.27% | 36.35% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
48 Neutral | $13.58B | ― | -28.77% | ― | -52.75% | 25.00% | |
40 Underperform | $1.27B | ― | 30.06% | ― | -30.65% | 77.62% | |
40 Underperform | $171.66M | ― | -154.01% | ― | ― | 45.81% | |
33 Underperform | $71.12M | ― | -106.64% | ― | -76.18% | 40.70% |
* Healthcare Sector Average
Performance Comparison
INO
Inovio Pharmaceuticals
1.95
-8.23
-80.84%
NVAX
Novavax
8.34
2.89
53.03%
OCGN
Ocugen
0.61
-0.38
-38.38%
VXRT
Vaxart
0.47
-0.72
-60.50%
MRNA
Moderna
35.61
-67.42
-65.44%
BNTX
BioNTech SE
108.78
17.51
19.18%
Inovio Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: 6.52% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with significant progress on the lead product candidate INO-3107 and financial discipline, though challenges remain with a manufacturing issue and cash runway concerns.Highlights
Progress on Lead Product Candidate INO-3107
Announced additional immunology data supporting the mechanism of action for INO-3107, potential for reducing surgeries in RRP patients, and presented full safety and efficacy data at scientific conferences.
Positive Pre-BLA Meeting with FDA
Held a positive pre-BLA meeting with the FDA for INO-3107, with BLA submission targeted for mid-2025.
Financial Discipline and Reduction in Operating Expenses
Total operating expenses dropped 24% from $35.9 million in Q3 2023 to $27.3 million in Q3 2024. The company has $84.8 million in cash, cash equivalents, and short-term investments.
Market Preparation and Strategic Choices for INO-3107
Developing a go-to-market strategy for INO-3107, including pricing in line with rare disease pricing and planning for a lean and efficient commercial footprint.
Lowlights
Manufacturing Issue with Device Component
Identified a manufacturing issue with the single-use component of the device for INO-3107, working on resolution.
Cash Runway Concerns
Cash runway projected to take the company into Q3 2025, with a net cash burn estimate of approximately $24 million for Q4 2024.
Company Guidance
During the third quarter of 2024, INOVIO provided guidance on several key metrics, focusing on the advancement of their lead product candidate, INO-3107, and the company's financial health. The company reported a net loss of $25.2 million, or $0.89 per share, which is an improvement compared to the $33.9 million loss, or $1.52 per share, from the same quarter in 2023. Operating expenses were reduced by 24% year-over-year, from $35.9 million to $27.3 million. INOVIO closed the quarter with $84.8 million in cash, cash equivalents, and short-term investments, projecting a cash runway into the third quarter of 2025. The company aims to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and plans to be launch-ready by the end of that year. They also highlighted the promising safety and efficacy data for INO-3107, indicating a 72% overall response rate in their Phase I/II trial, with 28% of patients requiring no surgical intervention post-treatment.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.